News & Updates

Welldoc Announces Expansion of Program with Leading Academic Medical Center to Evaluate BlueStar Digital Therapeutic as a Means of Transforming Population Health in Primary Care

October 15, 2018

Colum­bia, MD Octo­ber 15, 2018 – Well­doc® today announced that one of the world’s lead­ing aca­d­e­m­ic med­ical cen­ters is mov­ing into Phase 2 for ongo­ing Qual­i­ty Improve­ment research of BlueS­tar, its FDA-cleared dig­i­tal ther­a­peu­tic, in the treat­ment of patients with type 2 dia­betes with­in pri­ma­ry care. Prin­ci­pal inves­ti­ga­tor Daniel Hen­der­son, MD, MPH, a pri­ma­ry care provider at The Ambu­la­to­ry Prac­tice of the Future (APF) at Mass­a­chu­setts Gen­er­al Hos­pi­tal in Boston, will direct the Phase 2 test­ing of BlueS­tar. The product’s in-app coach deliv­ers per­son­al­ized, real-time feed­back, as well as a vari­ety of action­able and per­son­al­ized edu­ca­tion­al tools to engage patients with dia­betes and hyper­ten­sion.

Dia­betes is com­pli­cat­ed, and we are always look­ing for new ways to help patients bet­ter man­age their symp­toms,” said Dr. Hen­der­son. “This year, we’ll be eval­u­at­ing not only the impact this dig­i­tal health tech­nol­o­gy may have on patient care, but also bur­den reduc­tion for our providers and admin­is­tra­tive staff.”

By using a smart­phone appli­ca­tion to engage patients in their health and pro­vid­ing action­able data to the care team, the BlueS­tar plat­form is pro­vid­ing a new mech­a­nism for pri­ma­ry care clin­i­cians to embrace dia­betes pop­u­la­tion health. Use of BlueS­tar may also reduce the need/frequency for health­care providers to phys­i­cal­ly meet with patients and could poten­tial­ly improve clin­i­cal out­comes.

We are encour­aged to see this impor­tant pro­gram move into a sec­ond phase of imple­men­ta­tion and eval­u­a­tion with The Ambu­la­to­ry Prac­tice of the Future at Mass General—an orga­ni­za­tion com­mit­ted to inno­v­a­tive approach­es to pri­ma­ry care deliv­ery,” said Well­doc Vice Pres­i­dent, Clin­i­cal Ser­vices, Pro­grams and Research Malin­da Peeples, RN, MS, CDE. “We believe that it is only through col­lab­o­ra­tion across the health­care set­ting that the full poten­tial for dig­i­tal ther­a­peu­tics will be rec­og­nized and used to rev­o­lu­tion­ize and trans­form health­care deliv­ery.”

About BlueS­tar®

BlueS­tar, pow­ered by Well­doc, is an FDA-cleared, proven dig­i­tal ther­a­peu­tic that is an in-app coach engag­ing peo­ple with type 2 dia­betes. It deliv­ers per­son­al­ized, real-time feed­back, as well as dia­betes edu­ca­tion­al tools that are action­able and indi­vid­u­al­ized. Specif­i­cal­ly, Well­doc has devel­oped more than 30 peer-reviewed pub­li­ca­tions and pre­sen­ta­tions on BlueS­tar, includ­ing two ran­dom­ized, con­trolled clin­i­cal tri­als. Our clin­i­cal evi­dence shows a 1.7 to 2.0-point mean A1C reduc­tion for adults liv­ing with type 2 dia­betes who used BlueS­tar. In Novem­ber 2017, the IQVIA Insti­tute for Human Data Sci­ence (for­mer­ly Quintiles/IMS) named BlueS­tar the “top app” in clin­i­cal dia­betes treat­ment. BlueS­tar deliv­ers an esti­mat­ed aver­age cost sav­ings of $254-$271 per user per month, proven clin­i­cal out­comes and a net pro­mot­er mem­ber sat­is­fac­tion score of 70. For more infor­ma­tion on BlueS­tar, vis­it: www2.bluestardiabetes.com.

About Well­doc

Well­doc is a lead­ing dig­i­tal ther­a­peu­tic com­pa­ny rev­o­lu­tion­iz­ing chron­ic dis­ease man­age­ment to help trans­form lives. Our ground­break­ing tech­nol­o­gy is guid­ing indi­vid­u­als through the com­pli­cat­ed jour­ney of liv­ing with chron­ic dis­eases, with a goal of help­ing indi­vid­u­als self-man­age their con­di­tions to achieve sig­nif­i­cant clin­i­cal out­comes and cost sav­ings. We began our jour­ney by mas­ter­ing dia­betes man­age­ment solu­tions and are mov­ing rapid­ly into cre­at­ing addi­tion­al tools for man­ag­ing oth­er chron­ic dis­eases includ­ing hyper­ten­sion, chron­ic obstruc­tive pul­monary dis­ease (COPD) and con­ges­tive heart fail­ure (CHF). We are the first dig­i­tal health com­pa­ny based on a life sci­ence busi­ness mod­el with a foun­da­tion that is built on ran­dom­ized clin­i­cal tri­als that demon­strate sig­nif­i­cant clin­i­cal out­comes. We have tak­en an aggres­sive and inno­v­a­tive approach that uti­lizes sophis­ti­cat­ed log­ic, pre­cise algo­rithms, and arti­fi­cial intel­li­gence (AI), which inte­grates the most advanced mobile tech­nol­o­gy and behav­ioral insights. Well­doc part­ners with, col­lab­o­rates with, and is backed by top health­care com­pa­nies (includ­ing Mer­ck and John­son and John­son), lead­ing inno­va­tors, ded­i­cat­ed investors, and top mobile tech­nol­o­gy com­pa­nies (such as Sam­sung). For more infor­ma­tion, vis­it www.welldoc.com.